What’s Driving the Boom in Early Stage Biotech Funding?
The LabTech website noted that J&J Innovation is one of the many investors that are turning their gaze to the promise of early-stage research. J&J Innovation is following a strategy focusing on supporting ‘open innovation’, an approach that they believe could work where the traditional pharma approach has failed. J&J entered a collaboration with industry and charity partners to fund early-stage research into the neuroinflammation processes that might play a role in diseases. “We drive the ecosystem in terms of open innovation for specific areas where we think there is a need for more basic understanding,” said one researcher. This open innovation strategy is also behind J&J’s four ‘innovation centers’ in London, Shanghai, Boston and California, where the company brings together a network of scientists and investors.
Click here to read the full article.